贝伐珠单抗在恶性脑水肿治疗中的应用  

Application of bevacizumab for malignant brain edema

作　　者：于兰[1] 张小涛[1] 刘丽[1] 韩晓娜[1] Yu Lan Zhang Xiaotao Liu Li Han Xiaona(Cancer Prevention Center, Second Affiliated Hospital of Qingdao University, Qingdao Central （Cancer） Hospi- tal, Qingdao 266042, Chin)

机构地区：[1]青岛大学医学院第二附属医院青岛市中心 肿瘤 医院肿瘤防治中心,266042

出　　处：《国际肿瘤学杂志》2017年第1期41-44,共4页Journal of International Oncology

摘　　要：以贝伐珠单抗为主的抗血管生成药物通过减少血管通透性和血脑屏障破坏，能有效减轻恶性脑水肿，缓解临床症状，改善患者生命质量。贝伐珠单抗在治疗恶性脑水肿方面取得了积极的疗效，因此被认为是治疗恶性脑水肿的一种安全、有效的治疗手段。Anti-angiogenic drugs such as bevacizumab can effectively alleviate the patients′brain edema and clinical symptoms and improve the patients′life quality by reducing vascular permeability and the blood-brain barrier damage.Bevacizumab has got positive efficacy in the clinical,so that it is considered as an effective and safe treatment for malignant brain edema.

关 键 词：血管内皮生长因子类 脑水肿 脑肿瘤 贝伐珠单抗 

分 类 号：R739.4[医药卫生—肿瘤] R742[医药卫生—临床医学]